REVOTAR Biopharmaceuticals AG Company Profile

15:22 EDT 20th March 2018 | BioPortfolio

Revotar Biopharmaceuticals AG is a privately owned, independent German biopharmaceutical company located in Hennigsdorf close to Berlin. Revotar develops innovative small molecule anti-inflammatory drugs for indications such as asthma, psoriasis, sepsis, COPD and other inflammatory indications.Revotar was founded in 2000. The Company was endowed from the start with the asset bimosiamose, an innovative proprietary drug product (selectin antagonist) for the therapy of a variety of inflammatory disorders.
Our advanced drug candidate bimosiamose has passed three Phase II a (proof of concept) clinical trials in Asthma and Psoriasis.
Within our business build-up strategy, we focus on a subsegment of the R&D value chain of innovative drug discovery and drug development which can be managed with the resources of a start-up company. This subsegment ranges from validated targets, lead generation, lead optimization, preclinical development to Phase I/II clinical development (proof of concept/efficacy in man). After having successfully passed these stages Revotar is looking for strategic partners for co-development as well as licensee.
This business model offers at the same time future opportunity for growth towards a fully integrated pharmaceutical company (FIPCO).


Neuendorfstrasse 24a


Phone: 49 (0)3302 / 202 50 10
Fax: 49 (0)3302 / 202 50 11

News Articles [140 Associated News Articles listed on BioPortfolio]

-$0.19 EPS Expected for Keryx Biopharmaceuticals (KERX) This Quarter

Equities analysts predict that Keryx Biopharmaceuticals will announce earnings per share of for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Keryx Biopharmaceuti...

$18.60 Million in Sales Expected for Keryx Biopharmaceuticals (KERX) This Quarter

Wall Street brokerages predict that Keryx Biopharmaceuticals will post sales of $18.60 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates f...

Sienna Biopharmaceuticals nets $69.5mm in Nasdaq IPO

Aesthetics- and dermatology-focused Sienna Biopharmaceuticals Inc. (targeted topical delivery technology) netted $69.5mm through an initial public offering of 4.9mm shares (including the overallotment...

New international partnership promises great potential for next-generation biopharmaceuticals

There are a multitude of challenges associated with the production of next-generation biopharmaceuticals and vaccines. The Austrian Centre of Industrial Biotechnology and the BOKU - University of Natu...

Global and Chinese Biopharmaceuticals Industry, 2017 Market Research Report [Report Updated: 29122017] Prices from USD $3000

The 'Global and Chinese Biopharmaceuticals Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Biopharmaceuticals industry with a focus on...

Gallus BioPharmaceuticals: Mark Bamforth talks about saving jobs, local support and the importance of finding the right investment partners.

In this episode of PharmaTelevision News Review, Fintan Walton talks to Mark Bamforth, President and CEO of Gallus BioPharmaceuticals.

Comparing Sinovac Biotech (SVA) and Its Competitors

Sinovac Biotech is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it weigh in compared to its competitors? We will compare Sinovac Biotech to similar businesses based on...

Reviewing Sinovac Biotech (SVA) and The Competition

Sinovac Biotech is one of 49 publicly-traded companies in the "Biopharmaceuticals" industry, but how does it weigh in compared to its competitors? We will compare Sinovac Biotech to related companies ...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Thrombin human [Ethicon, Inc]

These highlights do not include all the information needed to use EVITHROM safely and effectively. See full prescribing information for EVITHROM.EVITHROM, Thrombin, Topical (Human)For Topical Use Only...

PubMed Articles [29 Associated PubMed Articles listed on BioPortfolio]

The importance of biosimilars medicines for private and statutory health insurance.

Patented biopharmaceuticals generate huge costs for private and statutory health insurance. Exactly ten years ago, off-patent biopharmaceuticals, also referred to as 'biosimilars medicines', became av...

A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery.

Aerosolized administration of biopharmaceuticals to the airways is a promising route for nasal and pulmonary drug delivery, but - in contrast to small molecules - little is known about the effects of ...

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.

In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. This review su...

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.

Ixekizumab (IXE) is an interleukin (IL)-17A antagonist approved for the treatment of adults with moderate-to-severe psoriasis.

Optimization of Capillary Zone Electrophoresis for Charge Heterogeneity testing of Biopharmaceuticals using Enhanced Method Development Principles.

Capillary zone electrophoresis is a well-established technique for charge heterogeneity testing of biopharmaceuticals 1. It is based on the differences between the ratios of net charge and hydrodynami...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Nicotine Vaccination and Nicotinic Receptor Occupancy

This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharm...

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children. In China, The overall impact of Hib-related infect...

Companies [185 Associated Companies listed on BioPortfolio]

REVOTAR Biopharmaceuticals AG

Revotar Biopharmaceuticals AG is a privately owned, independent German biopharmaceutical company located in Hennigsdorf close to Berlin. Revotar develops innovative small molecule anti-inflammatory dr...

Itero Biopharmaceuticals, Inc.

Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical an...

Bechtel Group Biopharmaceuticals Production

Design, construction, and validation of facilities for production of human biopharmaceuticals utilizing either fermentation or cell culture, facilities maintenance & operation for the virtual organiza...

BioRexis Pharmaceutical Corporation

BioRexis™ develops and produces novel biopharmaceuticals with superior pharmacology using efficient manufacturing systems. Many biopharmaceuticals face difficulties in development and commercializat...

Inspiration Biopharmaceuticals, Inc.

Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and improve the treat...

More Information about "REVOTAR Biopharmaceuticals AG" on BioPortfolio

We have published hundreds of REVOTAR Biopharmaceuticals AG news stories on BioPortfolio along with dozens of REVOTAR Biopharmaceuticals AG Clinical Trials and PubMed Articles about REVOTAR Biopharmaceuticals AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of REVOTAR Biopharmaceuticals AG Companies in our database. You can also find out about relevant REVOTAR Biopharmaceuticals AG Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Corporate Database Quicklinks

Searches Linking to this Company Record